Potential for overuse of corticosteroids and vasopressin in septic shock

Joe L. Hsu; Vincent Liu; Andrew J. Patterson; Greg S. Martin; Mark R. Nicolls; James A. Russell

doi:10.1186/cc11460

Potential for overuse of corticosteroids and vasopressin in septic shock

Joe L. Hsu, Vincent Liu, Andrew J. Patterson, Greg S. Martin, Mark R. Nicolls, James A. Russell

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	447
Journal	Critical Care
Volume	16
Issue number	5
DOIs	https://doi.org/10.1186/cc11460
State	Published - Sep 6 2012
Externally published	Yes

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine

Access to Document

10.1186/cc11460

Cite this

@article{8bc5e4bb1c3b4a6394aa91912c4d7e62,

title = "Potential for overuse of corticosteroids and vasopressin in septic shock",

author = "Hsu, {Joe L.} and Vincent Liu and Patterson, {Andrew J.} and Martin, {Greg S.} and Nicolls, {Mark R.} and Russell, {James A.}",

note = "Funding Information: JAR reports holding stock in Sirius Genomics Inc., which has submitted patents owned by the University of British Columbia (UBC) and licensed to Sirius Genomics, that is related to the genetics of sepsis and its treatment. The UBC has also submitted a patent related to the use of vasopressin in septic shock. JAR reports being an inventor on these patents. JAR reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing a selective V1a agonist), from Astra Zeneca (which is developing an anti-TNFα), from BioCritica (which used to sell activated protein C in the USA), from MeImmune, and from Sirius Genomics Inc. JAR reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, Astra Zeneca and Eli Lilly that is provided to and administered by the UBC. JAR has received speaking honoraria from Pfizer and Eli Lilly.",

year = "2012",

month = sep,

day = "6",

doi = "10.1186/cc11460",

language = "English (US)",

volume = "16",

journal = "Critical Care",

issn = "1364-8535",

publisher = "BioMed Central",

number = "5",

}

TY - JOUR

T1 - Potential for overuse of corticosteroids and vasopressin in septic shock

AU - Hsu, Joe L.

AU - Liu, Vincent

AU - Patterson, Andrew J.

AU - Martin, Greg S.

AU - Nicolls, Mark R.

AU - Russell, James A.

N1 - Funding Information: JAR reports holding stock in Sirius Genomics Inc., which has submitted patents owned by the University of British Columbia (UBC) and licensed to Sirius Genomics, that is related to the genetics of sepsis and its treatment. The UBC has also submitted a patent related to the use of vasopressin in septic shock. JAR reports being an inventor on these patents. JAR reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing a selective V1a agonist), from Astra Zeneca (which is developing an anti-TNFα), from BioCritica (which used to sell activated protein C in the USA), from MeImmune, and from Sirius Genomics Inc. JAR reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, Astra Zeneca and Eli Lilly that is provided to and administered by the UBC. JAR has received speaking honoraria from Pfizer and Eli Lilly.

PY - 2012/9/6

Y1 - 2012/9/6

UR - http://www.scopus.com/inward/record.url?scp=84867897419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867897419&partnerID=8YFLogxK

U2 - 10.1186/cc11460

DO - 10.1186/cc11460

M3 - Letter

C2 - 23102413

AN - SCOPUS:84867897419

SN - 1364-8535

VL - 16

JO - Critical Care

JF - Critical Care

IS - 5

M1 - 447

ER -

Potential for overuse of corticosteroids and vasopressin in septic shock

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this